Connect with us

Published

on

By Vijay Kumar Malesu Nov 23 2023 Reviewed by Lily Ramsey, LLM

In a recent study published in Journal of Clinical Medicine, researchers systematically reviewed and analyzed the therapeutic efficacy of low-dose local anesthetics (LAs) in various clinical conditions, highlighting gaps in current research for future exploration.

Study:  Therapeutic Use of Low-Dose Local Anesthetics in Pain, Inflammation, and Other Clinical Conditions: A Systematic Scoping Review . Image Credit: daniiD/Shutterstock.com Background 

Since the first use of cocaine as an LA by Carl Koller in 1894, LAs have evolved significantly in therapeutic applications. Initially utilized for their immediate pain-relieving properties, their scope expanded with the discovery of procaine in 1905 and its inflammation-reducing effects.

This evolution gave rise to neural therapy (NT), predominantly in Europe, employing LAs for more than just pain management. Modern applications extend to targeting the autonomic nervous system (ANS) to provide sustained relief from pain and other dysfunctions.

Further research is needed to comprehensively understand the scope, efficacy, and safety of low-dose local anesthetics in various conditions, as current studies vary in design, and a unified understanding is yet to be established. About the study 

In the present study, the researchers conducted a systematic scoping review using the Arksey and O’Malley framework, comprising five stages: defining the research question, identifying relevant studies, selecting studies, charting data, and summarizing and reporting results.

The review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for scoping reviews (PRISMA-ScR) guidelines, and the research question sought to understand the therapeutic applications of low-dose LAs in various medical conditions.

The team selected studies focusing solely on LAs, emphasizing measuring efficacy or safety. The review included a wide array of study designs, from experimental setups like randomized controlled trials (RCTs) to observational analyses including cohort and case-control studies. Systematic reviews, qualitative studies, and meta-analyses that met the inclusion criteria were also considered, excluding narrative reviews, expert opinions, and studies involving LAs combined with other treatments.

The literature search was comprehensive, covering major databases like MEDLINE, Cochrane Library, and LILACS, with no language or publication date restrictions. They supplemented this with searches on Google Scholar and references from included studies.

Two reviewers independently screened titles and abstracts, with full-text reviews for those meeting the inclusion criteria. Conflicts were resolved through discussion or a third reviewer's input. The study used Rayyan Qatar Computing Re­search Institute (QCRI) for data management during the screening phases. Related StoriesDay-to-day painkiller use doesn't lower empathy levels, but misuse might, according to recent surveyStudy finds pleasurable music and 'chills' predict music-induced hypoalgesiaNew insights into migraine etiology: the role of hepatocyte growth factor

Data extraction was thorough, capturing key information such as authorship, publication year, study objectives, population characteristics, study type, intervention details, outcomes, and main findings. Special attention was given to data on the safety of the interventions. A third reviewer resolved any discrepancies in data extraction.

Finally, the team performed a narrative synthesis of the results, using text and tables from the studies for a descriptive summary.

This synthesis not only outlined the characteristics and findings of the studies but also highlighted gaps in the evidence and offered potential interpretations and implications of the results. Study results 

The initial search across Medline, LILACS, and the Cochrane Library yielded 9614 publications, supplemented by 52 articles from citation searches and grey literature.

After duplicate removal, 7,670 publications were manually screened based on titles and abstracts, excluding 7,250 publications. This process left 420 articles for full-text assessment, with ten being inaccessible, and after thorough evaluation, 315 studies were further excluded. 

The researchers also considered 52 publications identified through citation searching, of which six could not be retrieved. Out of the 46 assessed for eligibility, 12 were excluded for being opinion articles, and 129 studies were included in the review. 

These included studies comprising 49 clinical trials (both non-randomized and randomized), 71 observational studies, and nine systematic reviews. The observational studies varied, including case reports or series, cohort studies, qualitative studies, and before-and-after studies.

The median patient number across these studies was 44. The studies primarily reported on procaine, lidocaine, and bupivacaine, focusing on their therapeutic applications and potential adverse effects.

Geographically, the studies spanned multiple countries, with the most contributions from Türkiye, Germany, the United States, and Cuba, among others. The median publication year was 2016, with a concentration of studies published between 2011 and March 2022.

These studies were predominantly published in general medical journals, although some appeared in specialized journals focused on pain management, neurology, psychiatry, and anesthesiology.

Regarding indications, the primary use of low-dose, short-acting LAs was in managing chronic pain, followed by acute pain. The most common conditions treated were musculoskeletal and/or myofascial pain and migraines. Additionally, 14% of the studies focused on non-pain-related indications.

In the studies, LAs were applied in various ways, including segmental application, local application, ganglion injections, and mixed approaches. The study’s Figure 5 highlights the evidence gaps in the literature regarding the types of indications and study designs.

The review found that 96.12% of the studies primarily assessed the efficacy of LAs, with a smaller portion focusing on safety. The key outcomes included pain relief, improvements in quality of life, reduced analgesic intake, and better scores on anxiety and depression scales.

While 53.48% of these studies also considered safety, reporting mild and transient adverse reactions, no severe adverse allergic responses or reactions were documented.

The study revealed that lidocaine and procaine were the most researched LAs, with lidocaine showing a slightly higher frequency of adverse events, though neither exhibited major adverse effects.

The interventions predominantly showed positive or potentially positive effects, with a minority reporting no effect or providing unclear evidence. A specific focus on acute stress revealed positive impacts, with studies on anxiety and depression as secondary outcomes showing varying degrees of improvement. Journal reference:

Vinyes D, Muñoz-Sellart M, Fischer L. (2023) Therapeutic Use of Low-Dose Local Anesthetics in Pain, Inflammation, and other Clinical Conditions: A Systematic Scoping Review. Journal of Clinical Medicine. doi:https://doi.org/10.3390/jcm12237221. https://www.mdpi.com/2077-0383/12/23/7221 

Continue Reading

Sports

Jets’ Scheifele misses G7 because of injury

Published

on

By

Jets' Scheifele misses G7 because of injury

Winnipeg forward Mark Scheifele did not play in Game 7 of the Jets’ first-round Stanley Cup playoff series against the St. Louis Blues on Sunday due to an undisclosed injury, coach Scott Arniel said.

Arniel ruled out Scheifele following the team’s morning skate. He was hurt in Game 5 — playing only 8:05 in the first period before exiting — and then did not travel with the Jets to St. Louis for Game 6. Arniel previously had said Scheifele was a game-time decision for Game 7.

Scheifele, 32, skated in a track suit Saturday, and Arniel told reporters the veteran was feeling better than he had the day before. Scheifele, however, was not able to participate in the Jets’ on-ice session by Sunday, quickly indicating he would not be available for the game.

Winnipeg held a 2-0 lead in the series over St. Louis before the Blues stormed back with a pair of wins to tie it, 2-2. The home team has won each game in the best-of-seven series so far.

The Jets’ challenge in closing out St. Louis only increases without Scheifele. Winnipeg already has been dealing with the uneven play of goaltender Connor Hellebuyck, a significant storyline in the series to date. Hellebuyck was pulled in all three of his starts at St. Louis while giving up a combined 16 goals on 66 shots (.758 SV%). In Game 6, Hellebuyck allowed four goals in only 5 minutes, 23 seconds of the second period.

Hellebuyck was Winnipeg’s backbone during the regular season, earning a Hart Trophy and Vezina Trophy nomination for his impeccable year (.925 SV%, 2.00 GAA).

Continue Reading

Sports

Stars expect Robertson, Heiskanen back in semis

Published

on

By

Stars expect Robertson, Heiskanen back in semis

Stars coach Pete DeBoer expects to have leading goal scorer Jason Robertson and standout defenseman Miro Heiskanen available in the Western Conference semifinals after both missed Dallas’ first-round series win over the Colorado Avalanche.

Following their thrilling Game 7 comeback victory over the Avalanche on Saturday night, the Stars await the winner of Sunday night’s Game 7 between the Winnipeg Jets and St. Louis Blues. If the Blues win, the Stars will have home-ice advantage in the best-of-seven series.

“I believe you’re going to see them both play in the second round, but I don’t know if it’s going to be Game 1 or Game 3 or Game 5,” DeBoer said after Saturday’s series clincher. “I consider them both day-to-day now, but there’s still some hurdles. It depends on when we start the series, how much time we have between now and Game 1. We’ll have a little better idea as we get closer.”

Robertson, 25, who posted 80 points (35 goals, 45 assists) in 82 games this season, suffered a lower-body injury in the regular-season finale April 16 and was considered week-to-week at the time.

Heiskanen hasn’t played since injuring his left knee in a Jan. 28 collision with Vegas Golden Knights forward Mark Stone. Initially expected to miss three to four months, the 25-year-old defenseman had surgery Feb. 4 and sat out the final 32 games of the regular season. In 50 games, he collected 25 points (five goals, 20 assists) and averaged 25:10 of ice time, which ranked fifth among NHL blueliners.

Continue Reading

Environment

U.S. crude oil prices fall more than 4% after OPEC+ agrees to surge production in June

Published

on

By

U.S. crude oil prices fall more than 4% after OPEC+ agrees to surge production in June

Logo of the Organization of the Petroleum Exporting Countries (OPEC)

Andrey Rudakov | Bloomberg | Getty Images

U.S. crude oil futures fell more than 4% on Sunday, after OPEC+ agreed to surge production for a second month.

U.S. crude was down $2.49, or 4.27%, to $55.80 a barrel shortly after trading opened. Global benchmark Brent fell $2.39, or 3.9%, to $58.90 per barrel. Oil prices have fallen more than 20% this year.

The eight producers in the group, led by Saudi Arabia, agreed on Saturday to increase output by another 411,000 barrels per day in June. The decision comes a month after OPEC+ surprised the market by agreeing to surge production in May by the same amount.

The June production hike is nearly triple the 140,000 bpd that Goldman Sachs had originally forecast. OPEC+ is bringing more than 800,000 bpd of additional supply to the market over the course of two months.

Oil prices in April posted the biggest monthly loss since 2021, as U.S. President Donald Trump’s tariffs have raised fears of a recession that will slow demand at the same time that OPEC+ is quickly increasing supply.

Oilfield service firms such as Baker Hughes and SLB are expecting investment in exploration and production to decline this year due to the weak price environment.

“The prospects of an oversupplied oil market, rising tariffs, uncertainty in Mexico and activity weakness in Saudi Arabia are collectively constraining international upstream spending levels,” Baker Hughes CEO Lorenzo Simonelli said on the company’s first-quarter earnings call on April 25.

Oil majors Chevron and Exxon reported first-quarter earnings last week that fell compared to the same period in 2024 due to lower oil prices.

Goldman is forecasting that U.S. crude and Brent prices will average $59 and $63 per barrel, respectively, this year.

Catch up on the latest energy news from CNBC Pro:

Continue Reading

Trending